On June 10, METiS Pharmaceuticals-P (07666.HK) fell 5.49% in regular trading, trading at HKD 12.27 per share, with trading volume of HKD 11.29 million. The stock has been in a sustained pullback since surging 173% on its listing debut on May 13.

On the news front, the company previously announced that the over-allotment option was fully exercised on June 5, involving 30.184 million H shares issued at the IPO price of HKD 10.50 per share. These over-allotment shares officially commenced trading on the Hong Kong Stock Exchange on June 10, directly increasing circulating supply and intensifying market selling pressure.

Meanwhile, the price stabilization period ended on June 7, meaning the mechanism that had previously supported the stock price has formally exited. Combined with the fact that certain international placement shares carry no lock-up period, profit-taking pressure continues to be released. These multiple factors have compounded to sustain the downward trajectory for the AI-driven drug delivery company since its post-IPO peak.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)